Literature DB >> 25127243

Prevention of invasive pneumococcal diseases: beyond cultures.

Carlos G Grijalva1, Marie R Griffin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25127243      PMCID： PMC4820063          DOI： 10.1016/S2213-2600(14)70143-2

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  5 in total

1.  Use of vaccine trials to estimate burden of disease.

Authors:  E Kim Mulholland
Journal:  J Health Popul Nutr       Date:  2004-09       Impact factor: 2.000

2.  Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs.

Authors:  G Vernet; S Saha; C Satzke; D H Burgess; M Alderson; J-F Maisonneuve; B W Beall; M C Steinhoff; K P Klugman
Journal:  Clin Microbiol Infect       Date:  2011-05       Impact factor: 8.067

3.  World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines.

Authors:  Shabir A Madhi; Keith P Klugman
Journal:  Vaccine       Date:  2006-09-18       Impact factor: 3.641

Review 4.  Use of vaccines as probes to define disease burden.

Authors:  Daniel R Feikin; J Anthony G Scott; Bradford D Gessner
Journal:  Lancet       Date:  2014-02-17       Impact factor: 79.321

5.  Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.

Authors:  Arto A Palmu; Jukka Jokinen; Dorota Borys; Heta Nieminen; Esa Ruokokoski; Lotta Siira; Taneli Puumalainen; Patricia Lommel; Marjan Hezareh; Marta Moreira; Lode Schuerman; Terhi M Kilpi
Journal:  Lancet       Date:  2012-11-16       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.